Condition (MeSH)
Multiple Endocrine Neoplasia Type 2a
ClinicalTrials.gov lists 15 trials for Multiple Endocrine Neoplasia Type 2a or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Multiple Endocrine Neoplasia Type 2a itself; the rest are tagged with a narrower condition beneath it.
When did Multiple Endocrine Neoplasia Type 2a trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 2 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 5 |
| 2015 | 1 |
| 2010 | 2 |
| 2007 | 1 |
| 2006 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Multiple Endocrine Neoplasia Type 2a trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Observational | 5 |
How many Multiple Endocrine Neoplasia Type 2a trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 9 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Multiple Endocrine Neoplasia Type 2a trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| GlaxoSmithKline | 2 |
| Hoffmann-La Roche | 2 |
| BioNTech SE | 1 |
| Boston Pharmaceuticals | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Multiple Endocrine Neoplasia Type 2a? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Veliparib | 1 |
| Pralsetinib | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| BNT316 | 1 |
| GSK3352589 | 1 |
| or carboplatin | 1 |
| ZD6474, Vandetanib | 1 |
| BNT116 | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Multiple Endocrine Neoplasia Type 2a trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 187 | 1 |
| Anaemia | 68 | 1 |
| Pneumonitis | 58 | 1 |
| Lung neoplasm malignant | 54 | 1 |
| Urinary tract infection | 52 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Multiple Endocrine Neoplasia Type 2a? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. | The Journal of clinical endocrinology and metabolism | 2025 | Yes |
| Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2018 | Yes |
| Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families. | Medicine | 2017 | Yes |
| Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. | Thyroid : official journal of the American Thyroid Association | 2015 | Yes |
| Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. | Oncogene | 2006 | Yes |
Showing 5 of 14 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Multiple endocrine neoplasia type 2A | 247698 | Exact | Orphadata Science knowledge files, Product 1 |
| Multiple endocrine neoplasia type 2A | 247698 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.